Sun Pharmaceutical Industries has begun the integration of Ranbaxy’s business following the successful closure of its merger. The merger has fortified Sun Pharma’s position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian Pharma company with significant lead in market share.
Sun Pharmaceutical Industries Ltd plans to acquire Ranbaxy Laboratories Ltd for US$ 4 billion. The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.
Sun Pharma and Taro Pharmaceutical Industries have entered into a merger agreement together with certain affiliates of Sun Pharma. Upon completion of the merger, Taro will become a privately held company, will be wholly owned by affiliates of Sun Pharma.